Bausch Health Reports Strong Q1 2025 Results with Revenue Growth and Strategic Refinancing

Bausch Health Companies ( (TSE:BHC) ) just unveiled an update.

Bausch Health Companies reported a 5% increase in first-quarter 2025 consolidated revenues, reaching $2.26 billion, with an organic growth of 6%. Despite a GAAP net loss of $58 million, the company maintained strong financial momentum, achieving its eighth consecutive quarter of year-over-year revenue and adjusted EBITDA growth. The company successfully completed a $7.9 billion refinancing to extend maturities and received a favorable court ruling in a case against the FDA. Bausch Health remains committed to unlocking shareholder value and maintaining its full-year 2025 financial guidance.

Spark’s Take on TSE:BHC Stock

According to Spark, TipRanks’ AI Analyst, TSE:BHC is a Neutral.

Bausch Health Companies’ overall score reflects its solid revenue growth and cash flow generation capabilities, countered by high leverage and ongoing profitability issues. Technical indicators and valuation metrics are unfavorable, while recent earnings calls and corporate events provide some optimism. Addressing financial stability and profitability concerns is crucial for long-term improvement.

To see Spark’s full report on TSE:BHC stock, click here.

More about Bausch Health Companies

Bausch Health Companies Inc. operates in the healthcare industry, focusing on pharmaceuticals, medical devices, and over-the-counter products. The company has a diverse portfolio with a market focus on eye health, gastroenterology, and dermatology.

YTD Price Performance: -31.86%

Average Trading Volume: 2,648,082

Technical Sentiment Signal: Strong Buy

Current Market Cap: $2B

For an in-depth examination of BHC stock, go to TipRanks’ Stock Analysis page.